The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE)...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; pp. 23713 - 10
Main Authors Shimizu, Jun, Sasaki, Tadahiro, Yamanaka, Atsushi, Ichihara, Yoko, Koketsu, Ritsuko, Samune, Yoshihiro, Cruz, Pedro, Sato, Kei, Tanga, Naomi, Yoshimura, Yuka, Murakami, Ami, Yamada, Misuzu, Itoi, Kiyoe, Nakayama, Emi E., Miyazaki, Kazuo, Shioda, Tatsuo
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 09.12.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/250/254
631/326/596/4130
ACE2
Angiotensin-converting enzyme 2
Angiotensin-Converting Enzyme 2 - metabolism
Antibodies
Antibodies, Neutralizing - immunology
Antibodies, Viral - immunology
Antibody-Dependent Enhancement
Cell Line
Cell lines
Clinical trials
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - metabolism
COVID-19 vaccines
Dengue fever
Humanities and Social Sciences
Humans
Infections
Interleukin 6
Interleukin-6 - metabolism
multidisciplinary
Myeloid Cells - immunology
Myeloid Cells - metabolism
Patients
SARS-CoV-2 - immunology
Science
Science (multidisciplinary)
Serine Endopeptidases - metabolism
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccine development
Vaccines
Vector-borne diseases
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-021-03273-0

Cover

Abstract Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35–40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.
AbstractList Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35–40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.
Abstract Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35–40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35-40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35-40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.
ArticleNumber 23713
Author Murakami, Ami
Yamada, Misuzu
Sato, Kei
Tanga, Naomi
Nakayama, Emi E.
Koketsu, Ritsuko
Yoshimura, Yuka
Sasaki, Tadahiro
Yamanaka, Atsushi
Cruz, Pedro
Samune, Yoshihiro
Shioda, Tatsuo
Miyazaki, Kazuo
Ichihara, Yoko
Itoi, Kiyoe
Shimizu, Jun
Author_xml – sequence: 1
  givenname: Jun
  surname: Shimizu
  fullname: Shimizu, Jun
  organization: MiCAN Technologies Inc
– sequence: 2
  givenname: Tadahiro
  surname: Sasaki
  fullname: Sasaki, Tadahiro
  organization: Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University
– sequence: 3
  givenname: Atsushi
  surname: Yamanaka
  fullname: Yamanaka, Atsushi
  organization: MiCAN Technologies Inc., Faculty of Tropical Medicine, Mahidol-Osaka Center for Infectious Diseases, Mahidol University
– sequence: 4
  givenname: Yoko
  surname: Ichihara
  fullname: Ichihara, Yoko
  organization: MiCAN Technologies Inc
– sequence: 5
  givenname: Ritsuko
  surname: Koketsu
  fullname: Koketsu, Ritsuko
  organization: Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University
– sequence: 6
  givenname: Yoshihiro
  surname: Samune
  fullname: Samune, Yoshihiro
  organization: Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University
– sequence: 7
  givenname: Pedro
  surname: Cruz
  fullname: Cruz, Pedro
  organization: MiCAN Technologies Inc
– sequence: 8
  givenname: Kei
  surname: Sato
  fullname: Sato, Kei
  organization: MiCAN Technologies Inc
– sequence: 9
  givenname: Naomi
  surname: Tanga
  fullname: Tanga, Naomi
  organization: MiCAN Technologies Inc
– sequence: 10
  givenname: Yuka
  surname: Yoshimura
  fullname: Yoshimura, Yuka
  organization: MiCAN Technologies Inc
– sequence: 11
  givenname: Ami
  surname: Murakami
  fullname: Murakami, Ami
  organization: MiCAN Technologies Inc
– sequence: 12
  givenname: Misuzu
  surname: Yamada
  fullname: Yamada, Misuzu
  organization: MiCAN Technologies Inc
– sequence: 13
  givenname: Kiyoe
  surname: Itoi
  fullname: Itoi, Kiyoe
  organization: MiCAN Technologies Inc
– sequence: 14
  givenname: Emi E.
  surname: Nakayama
  fullname: Nakayama, Emi E.
  organization: Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University
– sequence: 15
  givenname: Kazuo
  surname: Miyazaki
  fullname: Miyazaki, Kazuo
  email: kmiyazaki@micantechnologies.com
  organization: MiCAN Technologies Inc
– sequence: 16
  givenname: Tatsuo
  surname: Shioda
  fullname: Shioda, Tatsuo
  email: shioda@biken.osaka-u.ac.jp
  organization: Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Faculty of Tropical Medicine, Mahidol-Osaka Center for Infectious Diseases, Mahidol University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34887501$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAQxyNURMvSF-CALHHhEvBXbOeChJavlVbqpXC1HHuy6yprBztB6o3X4PV4Ery7pbQ91Ad7NP7N3zOeeV6dhBigql4S_JZgpt5lTppW1ZiSGjMqWY2fVGcU86amjNKTO_ZpdZ7zFS6roS0n7bPqlHGlZIPJWZUvt4DGOEGYvBlQ7NHy4vvqY01aNJrJF3f-8-s3ypAMmiKyZs6ATIG76K5rByMEVyAEYWuChd3eLiI-9GAnH0NhHVqta4HGFN188L2onvZmyHB-cy6qb58_XS6_1uuLL6vlh3VtG46nmvOe4UYZI6wwoutkL5S1bam-kw1vVEsIJ0Rx2VnXSStkIywFjg0GRjizbFGtjroumis9Jr8z6VpH4_XBEdNGmzR5O4BuCaecgaRcMi6kMx1texBOdaJvmeuL1vuj1jh3O3C21JnMcE_0_k3wW72JP7USAivBisCbG4EUf8yQJ73z2cIwmABxzpoWrGFKElnQ1w_QqzinUL7qQFFBZUsL9epuRrep_OttAegRsCnmnKC_RQjW-xnSxxnSZYb0YYbKvqjUgyDrJ7PvWqnKD4-HsmNoLu-EDaT_aT8S9Rck19pZ
CitedBy_id crossref_primary_10_1038_s41392_024_02043_4
crossref_primary_10_3390_vaccines11040773
crossref_primary_10_3390_microorganisms11041015
crossref_primary_10_3390_molecules27123851
crossref_primary_10_1038_s41598_022_19993_w
crossref_primary_10_3390_v15102018
crossref_primary_10_3390_pathogens13121109
crossref_primary_10_2147_IJN_S427990
crossref_primary_10_1016_j_biopha_2022_113946
crossref_primary_10_1016_j_lfs_2023_121907
crossref_primary_10_1111_imr_13401
crossref_primary_10_1038_s41598_022_12252_y
crossref_primary_10_1016_j_intimp_2022_108943
crossref_primary_10_1038_s41598_024_77969_4
crossref_primary_10_1016_j_micinf_2024_105464
Cites_doi 10.1056/NEJMoa1506223
10.1056/NEJMc2028468
10.1111/imr.12367
10.3389/fimmu.2020.01446
10.1126/science.abb8925
10.1016/s0092-8674(00)80693-5
10.3201/eid2704.210138
10.1164/rccm.200407-857OC
10.1002/rmv.2141
10.1101/2021.01.03.425141
10.1038/gt.2012.59
10.1016/j.cyto.2020.155256
10.1172/jci.insight.140289
10.1016/j.cell.2021.05.032
10.1371/journal.pone.0152384
10.1038/s41586-020-03148-w
10.1016/s0140-6736(21)00183-5
10.1016/s2213-2600(20)30193-4
10.1099/jgv.0.001119
10.1038/s41467-020-19568-1
10.1016/s2213-2600(20)30404-5
10.1128/jvi.02015-19
10.1016/j.cell.2021.06.021
10.4049/jimmunol.144.8.3183
10.1128/jvi.75.5.2324-2330.2001
10.1101/2020.12.21.20248640
10.1038/s41577-020-00410-0
10.1016/j.cell.2020.02.052
10.1093/cid/ciaa449
10.1016/j.chom.2020.04.009
10.1186/s41232-020-00146-3
10.1089/088282403763635465
10.3390/vaccines9010054
10.1016/j.cell.2020.04.035
10.1016/s0140-6736(88)91657-1
10.1016/s2666-5247(20)30004-5
10.1038/s41586-020-2538-8
10.1016/j.humimm.2013.05.017
10.1038/s41564-020-00789-5
10.1016/j.jviromet.2009.09.018
10.1002/JLB.3COVR0520-272R
10.1016/j.heliyon.2020.e05407
10.1016/j.vaccine.2008.10.087
10.1016/j.celrep.2021.108699
10.1016/s0140-6736(20)30183-5
10.2807/1560-7917.ES.2020.26.1.2002106
10.1101/2020.10.08.20209114
10.1016/j.jclinepi.2017.11.019
10.1126/science.abc6027
10.1186/1743-422x-11-82
10.1016/j.tim.2017.10.004
10.1016/j.cell.2020.08.025
10.1016/j.eclinm.2021.100734
10.1111/cei.12612
ContentType Journal Article
Copyright The Author(s) 2021
2021. The Author(s).
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: 2021. The Author(s).
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-03273-0
DatabaseName Springer Nature OA/Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

Publicly Available Content Database

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 10
ExternalDocumentID oai_doaj_org_article_914243e72473467dab29fe6d8b6f93df
PMC8660863
34887501
10_1038_s41598_021_03273_0
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: the Japan Agency for Medical Research and Development (AMED)
  grantid: JP20he0822004
– fundername: ;
  grantid: JP20he0822004
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-44f3058aa6c6a6bb7f68cc9103b75458911411847bcdb7c6756c2e40a0e3143c3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:27:38 EDT 2025
Thu Aug 21 14:32:25 EDT 2025
Fri Jul 11 16:04:31 EDT 2025
Wed Aug 13 01:46:37 EDT 2025
Thu Jan 02 22:55:20 EST 2025
Tue Jul 01 01:34:00 EDT 2025
Thu Apr 24 23:09:40 EDT 2025
Fri Feb 21 02:39:41 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-44f3058aa6c6a6bb7f68cc9103b75458911411847bcdb7c6756c2e40a0e3143c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2608262792?pq-origsite=%requestingapplication%
PMID 34887501
PQID 2608262792
PQPubID 2041939
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_914243e72473467dab29fe6d8b6f93df
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8660863
proquest_miscellaneous_2608538717
proquest_journals_2608262792
pubmed_primary_34887501
crossref_primary_10_1038_s41598_021_03273_0
crossref_citationtrail_10_1038_s41598_021_03273_0
springer_journals_10_1038_s41598_021_03273_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-09
PublicationDateYYYYMMDD 2021-12-09
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-09
  day: 09
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Lee, Wheatley, Kent, DeKosky (CR11) 2020; 5
Ziegler (CR41) 2020; 181
Fujino (CR56) 2021
Leisman (CR37) 2020; 8
Wan (CR5) 2020
Arvin (CR12) 2020; 584
Taylor (CR27) 2015; 268
Wang, Jiang, Chen, Montaner (CR31) 2020; 108
Yamanaka, Miyazaki, Shimizu, Senju (CR2) 2020; 6
Chu (CR16) 2020; 1
Tirado, Yoon (CR28) 2003; 16
Mannar, Leopold, Subramaniam (CR43) 2021
Wu (CR44) 2020
Imamura (CR20) 2016; 11
Giamarellos-Bourboulis (CR22) 2020; 27
Haruta (CR18) 2013; 20
Huisman, Martina, Rimmelzwaan, Gruters, Osterhaus (CR8) 2009; 27
Sariol, Nogueira, Vasilakis (CR3) 2018; 26
Li (CR45) 2021; 184
Littaua, Kurane, Ennis (CR26) 1990; 144
Dans, Dans, Lansang, Silvestre, Guyatt (CR10) 2018; 95
Hadjadj (CR29) 2020; 369
Liu (CR46) 2021
Wang (CR42) 2020; 11
Wilson (CR35) 2020
Grant (CR14) 2021; 590
Yamayoshi (CR53) 2021; 32
Moore, June (CR32) 2020; 368
Zhou (CR47) 2021; 34
Yip (CR4) 2014; 11
Robinson, Montefiori, Mitchell (CR6) 1988; 1
Jiang (CR36) 2005; 171
Tegally (CR55) 2020
Coomes, Haghbayan (CR39) 2020; 30
Manh (CR25) 2018; 99
Huang (CR30) 2020; 395
Leung, Shum, Leung, Lam, Wu (CR54) 2021
Cloutier (CR17) 2020; 136
Geijtenbeek (CR23) 2000; 100
Bournazos, Gupta, Ravetch (CR13) 2020; 20
Rutkowska-Zapala (CR40) 2015; 181
Moi, Lim, Kotaki, Takasaki, Kurane (CR1) 2010; 163
Hui (CR15) 2020; 8
Kutsuna, Asai, Matsunaga (CR50) 2020; 383
Takada, Watanabe, Okazaki, Kida, Kawaoka (CR7) 2001; 75
Sabino (CR48) 2021; 397
Hojyo (CR34) 2020; 40
Karwaciak, Sałkowska, Karaś, Dastych, Ratajewski (CR38) 2021
Ragab, Salah Eldin, Taeimah, Khattab, Salem (CR33) 2020; 11
Haruta (CR19) 2013; 74
Kaneko (CR52) 2020; 183
Bölke, Matuschek, Fischer (CR49) 2020; 383
Terpos, Mentis, Dimopoulos (CR51) 2020; 383
Hoffmann (CR24) 2020; 181
Chen (CR21) 2020; 71
Hadinegoro (CR9) 2015; 373
EC Sabino (3273_CR48) 2021; 397
T Fujino (3273_CR56) 2021
SR Hadinegoro (3273_CR9) 2015; 373
AL Dans (3273_CR10) 2018; 95
X Chen (3273_CR21) 2020; 71
A Yamanaka (3273_CR2) 2020; 6
M Rutkowska-Zapala (3273_CR40) 2015; 181
M Hoffmann (3273_CR24) 2020; 181
I Karwaciak (3273_CR38) 2021
Y Zhou (3273_CR47) 2021; 34
CA Sariol (3273_CR3) 2018; 26
S Bournazos (3273_CR13) 2020; 20
M Haruta (3273_CR18) 2013; 20
N Kaneko (3273_CR52) 2020; 183
RA Grant (3273_CR14) 2021; 590
M Haruta (3273_CR19) 2013; 74
J Wang (3273_CR31) 2020; 108
K Leung (3273_CR54) 2021
DE Leisman (3273_CR37) 2020; 8
S Wang (3273_CR42) 2020; 11
Y Wan (3273_CR5) 2020
KPY Hui (3273_CR15) 2020; 8
D Ragab (3273_CR33) 2020; 11
F Wu (3273_CR44) 2020
A Takada (3273_CR7) 2001; 75
EJ Giamarellos-Bourboulis (3273_CR22) 2020; 27
S Yamayoshi (3273_CR53) 2021; 32
JB Moore (3273_CR32) 2020; 368
TB Geijtenbeek (3273_CR23) 2000; 100
S Hojyo (3273_CR34) 2020; 40
CGK Ziegler (3273_CR41) 2020; 181
EA Coomes (3273_CR39) 2020; 30
Y Liu (3273_CR46) 2021
WE Robinson Jr (3273_CR6) 1988; 1
E Terpos (3273_CR51) 2020; 383
WS Lee (3273_CR11) 2020; 5
ML Moi (3273_CR1) 2010; 163
SM Tirado (3273_CR28) 2003; 16
S Kutsuna (3273_CR50) 2020; 383
AM Arvin (3273_CR12) 2020; 584
R Littaua (3273_CR26) 1990; 144
A Taylor (3273_CR27) 2015; 268
H Tegally (3273_CR55) 2020
W Huisman (3273_CR8) 2009; 27
DH Manh (3273_CR25) 2018; 99
Y Jiang (3273_CR36) 2005; 171
C Huang (3273_CR30) 2020; 395
M Cloutier (3273_CR17) 2020; 136
D Li (3273_CR45) 2021; 184
MS Yip (3273_CR4) 2014; 11
Y Imamura (3273_CR20) 2016; 11
D Mannar (3273_CR43) 2021
H Chu (3273_CR16) 2020; 1
J Hadjadj (3273_CR29) 2020; 369
E Bölke (3273_CR49) 2020; 383
JG Wilson (3273_CR35) 2020
References_xml – volume: 373
  start-page: 1195
  year: 2015
  end-page: 1206
  ident: CR9
  article-title: Efficacy and long-term safety of a dengue vaccine in regions of endemic disease
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1506223
– volume: 383
  start-page: 1694
  year: 2020
  end-page: 1695
  ident: CR49
  article-title: Loss of anti-Sars-Cov-2 antibodies in mild covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– volume: 268
  start-page: 340
  year: 2015
  end-page: 364
  ident: CR27
  article-title: Fc receptors in antibody-dependent enhancement of viral infections
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12367
– volume: 383
  start-page: 1695
  year: 2020
  ident: CR51
  article-title: Loss of anti-Sars-Cov-2 antibodies in mild covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– volume: 11
  start-page: 1446
  year: 2020
  ident: CR33
  article-title: The COVID-19 cytokine storm; What we know so far
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.01446
– volume: 368
  start-page: 473
  year: 2020
  end-page: 474
  ident: CR32
  article-title: Cytokine release syndrome in severe COVID-19
  publication-title: Science
  doi: 10.1126/science.abb8925
– volume: 100
  start-page: 575
  year: 2000
  end-page: 585
  ident: CR23
  article-title: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
  publication-title: Cell
  doi: 10.1016/s0092-8674(00)80693-5
– year: 2021
  ident: CR56
  article-title: Novel SARS-CoV-2 variant identified in travelers from Brazil to Japan
  publication-title: Emerg. Infect. Dis. J.
  doi: 10.3201/eid2704.210138
– volume: 171
  start-page: 850
  year: 2005
  end-page: 857
  ident: CR36
  article-title: Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.200407-857OC
– volume: 30
  start-page: 1
  year: 2020
  end-page: 9
  ident: CR39
  article-title: Interleukin-6 in Covid-19: A systematic review and meta-analysis
  publication-title: Rev. Med. Virol.
  doi: 10.1002/rmv.2141
– year: 2021
  ident: CR43
  article-title: Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
  publication-title: BioRxiv.
  doi: 10.1101/2021.01.03.425141
– volume: 20
  start-page: 504
  year: 2013
  end-page: 513
  ident: CR18
  article-title: TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells
  publication-title: Gene Ther.
  doi: 10.1038/gt.2012.59
– volume: 136
  start-page: 155256
  year: 2020
  ident: CR17
  article-title: ADE and hyperinflammation in SARS-CoV2 infection-comparison with dengue hemorrhagic fever and feline infectious peritonitis
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2020.155256
– year: 2020
  ident: CR35
  article-title: Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
  publication-title: JCI Insight.
  doi: 10.1172/jci.insight.140289
– year: 2021
  ident: CR46
  article-title: An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
  publication-title: Cell
  doi: 10.1016/j.cell.2021.05.032
– volume: 11
  start-page: e0152384
  year: 2016
  ident: CR20
  article-title: Generation of large numbers of antigen-expressing human dendritic cells using CD14-ML technology
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0152384
– volume: 590
  start-page: 635
  year: 2021
  end-page: 641
  ident: CR14
  article-title: Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
  publication-title: Nature
  doi: 10.1038/s41586-020-03148-w
– volume: 397
  start-page: 452
  year: 2021
  end-page: 455
  ident: CR48
  article-title: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00183-5
– volume: 8
  start-page: 687
  year: 2020
  end-page: 695
  ident: CR15
  article-title: Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: An analysis in ex-vivo and in-vitro cultures
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(20)30193-4
– volume: 99
  start-page: 1239
  year: 2018
  end-page: 1247
  ident: CR25
  article-title: iPS cell serves as a source of dendritic cells for in vitro dengue virus infection model
  publication-title: J. Gen. Virol.
  doi: 10.1099/jgv.0.001119
– volume: 11
  start-page: 5752
  year: 2020
  ident: CR42
  article-title: Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19568-1
– volume: 8
  start-page: 1233
  year: 2020
  end-page: 1244
  ident: CR37
  article-title: Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(20)30404-5
– year: 2020
  ident: CR5
  article-title: Molecular mechanism for antibody-dependent enhancement of coronavirus entry
  publication-title: J. Virol.
  doi: 10.1128/jvi.02015-19
– volume: 383
  start-page: 1695
  year: 2020
  end-page: 1696
  ident: CR50
  article-title: Loss of anti-Sars-Cov-2 antibodies in mild covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– volume: 184
  start-page: 4203
  year: 2021
  end-page: 4219
  ident: CR45
  article-title: In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
  publication-title: Cell
  doi: 10.1016/j.cell.2021.06.021
– volume: 144
  start-page: 3183
  year: 1990
  end-page: 3186
  ident: CR26
  article-title: Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.144.8.3183
– volume: 75
  start-page: 2324
  year: 2001
  end-page: 2330
  ident: CR7
  article-title: Infectivity-enhancing antibodies to Ebola virus glycoprotein
  publication-title: J. Virol.
  doi: 10.1128/jvi.75.5.2324-2330.2001
– year: 2020
  ident: CR55
  article-title: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
  publication-title: MedRxiv.
  doi: 10.1101/2020.12.21.20248640
– volume: 20
  start-page: 633
  year: 2020
  end-page: 643
  ident: CR13
  article-title: The role of IgG Fc receptors in antibody-dependent enhancement
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00410-0
– volume: 181
  start-page: 271
  year: 2020
  end-page: 280
  ident: CR24
  article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 71
  start-page: 1937
  year: 2020
  end-page: 1942
  ident: CR21
  article-title: Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa449
– volume: 27
  start-page: 992
  year: 2020
  end-page: 1000
  ident: CR22
  article-title: Complex immune dysregulation in COVID-19 patients with severe respiratory failure
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.04.009
– volume: 40
  start-page: 37
  year: 2020
  ident: CR34
  article-title: How COVID-19 induces cytokine storm with high mortality
  publication-title: Inflamm. Regen.
  doi: 10.1186/s41232-020-00146-3
– volume: 16
  start-page: 69
  year: 2003
  end-page: 86
  ident: CR28
  article-title: Antibody-dependent enhancement of virus infection and disease
  publication-title: Viral Immunol.
  doi: 10.1089/088282403763635465
– year: 2021
  ident: CR38
  article-title: Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophages-potential implications for cytokine storm syndrome
  publication-title: Vaccines (Basel).
  doi: 10.3390/vaccines9010054
– volume: 181
  start-page: 1016
  year: 2020
  end-page: 1035
  ident: CR41
  article-title: SARS-CoV-2 Receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues
  publication-title: Cell
  doi: 10.1016/j.cell.2020.04.035
– volume: 1
  start-page: 790
  year: 1988
  end-page: 794
  ident: CR6
  article-title: Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
  publication-title: Lancet
  doi: 10.1016/s0140-6736(88)91657-1
– volume: 1
  start-page: e14
  year: 2020
  end-page: e23
  ident: CR16
  article-title: Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study
  publication-title: The Lancet Microbe
  doi: 10.1016/s2666-5247(20)30004-5
– volume: 584
  start-page: 353
  year: 2020
  end-page: 363
  ident: CR12
  article-title: A perspective on potential antibody-dependent enhancement of SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2538-8
– volume: 74
  start-page: 1400
  year: 2013
  end-page: 1408
  ident: CR19
  article-title: Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2013.05.017
– volume: 5
  start-page: 1185
  year: 2020
  end-page: 1191
  ident: CR11
  article-title: Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-00789-5
– volume: 163
  start-page: 205
  year: 2010
  end-page: 209
  ident: CR1
  article-title: Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2009.09.018
– volume: 108
  start-page: 17
  year: 2020
  end-page: 41
  ident: CR31
  article-title: Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts
  publication-title: J. Leukoc. Biol.
  doi: 10.1002/JLB.3COVR0520-272R
– volume: 6
  start-page: e05407
  year: 2020
  ident: CR2
  article-title: Dengue virus susceptibility in novel immortalized myeloid cells
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e05407
– volume: 27
  start-page: 505
  year: 2009
  end-page: 512
  ident: CR8
  article-title: Vaccine-induced enhancement of viral infections
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.10.087
– volume: 34
  start-page: 108699
  year: 2021
  ident: CR47
  article-title: Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.108699
– volume: 395
  start-page: 497
  year: 2020
  end-page: 506
  ident: CR30
  article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(20)30183-5
– year: 2021
  ident: CR54
  article-title: Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020
  publication-title: Euro Surveill.
  doi: 10.2807/1560-7917.ES.2020.26.1.2002106
– year: 2020
  ident: CR44
  article-title: Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: Studies based on cellular and structural biology analysis
  publication-title: MedRxiv.
  doi: 10.1101/2020.10.08.20209114
– volume: 95
  start-page: 137
  year: 2018
  end-page: 139
  ident: CR10
  article-title: Controversy and debate on dengue vaccine series-paper 1: Review of a licensed dengue vaccine: Inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/j.jclinepi.2017.11.019
– volume: 369
  start-page: 718
  year: 2020
  end-page: 724
  ident: CR29
  article-title: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
  publication-title: Science
  doi: 10.1126/science.abc6027
– volume: 11
  start-page: 82
  year: 2014
  ident: CR4
  article-title: Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
  publication-title: Virol. J.
  doi: 10.1186/1743-422x-11-82
– volume: 26
  start-page: 186
  year: 2018
  end-page: 190
  ident: CR3
  article-title: A tale of two viruses: Does heterologous flavivirus immunity enhance Zika disease?
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2017.10.004
– volume: 183
  start-page: 143
  year: 2020
  end-page: 157
  ident: CR52
  article-title: Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.025
– volume: 32
  start-page: 100734
  year: 2021
  ident: CR53
  article-title: Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100734
– volume: 181
  start-page: 126
  year: 2015
  end-page: 132
  ident: CR40
  article-title: Human monocyte subsets exhibit divergent angiotensin I-converting activity
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/cei.12612
– year: 2020
  ident: 3273_CR44
  publication-title: MedRxiv.
  doi: 10.1101/2020.10.08.20209114
– volume: 373
  start-page: 1195
  year: 2015
  ident: 3273_CR9
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1506223
– volume: 171
  start-page: 850
  year: 2005
  ident: 3273_CR36
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.200407-857OC
– volume: 397
  start-page: 452
  year: 2021
  ident: 3273_CR48
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00183-5
– volume: 1
  start-page: 790
  year: 1988
  ident: 3273_CR6
  publication-title: Lancet
  doi: 10.1016/s0140-6736(88)91657-1
– volume: 369
  start-page: 718
  year: 2020
  ident: 3273_CR29
  publication-title: Science
  doi: 10.1126/science.abc6027
– volume: 181
  start-page: 126
  year: 2015
  ident: 3273_CR40
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/cei.12612
– volume: 11
  start-page: 1446
  year: 2020
  ident: 3273_CR33
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.01446
– year: 2021
  ident: 3273_CR54
  publication-title: Euro Surveill.
  doi: 10.2807/1560-7917.ES.2020.26.1.2002106
– year: 2020
  ident: 3273_CR55
  publication-title: MedRxiv.
  doi: 10.1101/2020.12.21.20248640
– volume: 1
  start-page: e14
  year: 2020
  ident: 3273_CR16
  publication-title: The Lancet Microbe
  doi: 10.1016/s2666-5247(20)30004-5
– volume: 20
  start-page: 504
  year: 2013
  ident: 3273_CR18
  publication-title: Gene Ther.
  doi: 10.1038/gt.2012.59
– volume: 11
  start-page: e0152384
  year: 2016
  ident: 3273_CR20
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0152384
– volume: 181
  start-page: 1016
  year: 2020
  ident: 3273_CR41
  publication-title: Cell
  doi: 10.1016/j.cell.2020.04.035
– volume: 71
  start-page: 1937
  year: 2020
  ident: 3273_CR21
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa449
– volume: 183
  start-page: 143
  year: 2020
  ident: 3273_CR52
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.025
– volume: 268
  start-page: 340
  year: 2015
  ident: 3273_CR27
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12367
– volume: 395
  start-page: 497
  year: 2020
  ident: 3273_CR30
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(20)30183-5
– volume: 184
  start-page: 4203
  year: 2021
  ident: 3273_CR45
  publication-title: Cell
  doi: 10.1016/j.cell.2021.06.021
– volume: 163
  start-page: 205
  year: 2010
  ident: 3273_CR1
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2009.09.018
– volume: 590
  start-page: 635
  year: 2021
  ident: 3273_CR14
  publication-title: Nature
  doi: 10.1038/s41586-020-03148-w
– volume: 368
  start-page: 473
  year: 2020
  ident: 3273_CR32
  publication-title: Science
  doi: 10.1126/science.abb8925
– year: 2021
  ident: 3273_CR46
  publication-title: Cell
  doi: 10.1016/j.cell.2021.05.032
– year: 2020
  ident: 3273_CR5
  publication-title: J. Virol.
  doi: 10.1128/jvi.02015-19
– volume: 75
  start-page: 2324
  year: 2001
  ident: 3273_CR7
  publication-title: J. Virol.
  doi: 10.1128/jvi.75.5.2324-2330.2001
– volume: 16
  start-page: 69
  year: 2003
  ident: 3273_CR28
  publication-title: Viral Immunol.
  doi: 10.1089/088282403763635465
– volume: 584
  start-page: 353
  year: 2020
  ident: 3273_CR12
  publication-title: Nature
  doi: 10.1038/s41586-020-2538-8
– volume: 27
  start-page: 992
  year: 2020
  ident: 3273_CR22
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.04.009
– volume: 11
  start-page: 82
  year: 2014
  ident: 3273_CR4
  publication-title: Virol. J.
  doi: 10.1186/1743-422x-11-82
– volume: 32
  start-page: 100734
  year: 2021
  ident: 3273_CR53
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100734
– volume: 6
  start-page: e05407
  year: 2020
  ident: 3273_CR2
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e05407
– volume: 136
  start-page: 155256
  year: 2020
  ident: 3273_CR17
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2020.155256
– volume: 100
  start-page: 575
  year: 2000
  ident: 3273_CR23
  publication-title: Cell
  doi: 10.1016/s0092-8674(00)80693-5
– volume: 34
  start-page: 108699
  year: 2021
  ident: 3273_CR47
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.108699
– volume: 95
  start-page: 137
  year: 2018
  ident: 3273_CR10
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/j.jclinepi.2017.11.019
– volume: 26
  start-page: 186
  year: 2018
  ident: 3273_CR3
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2017.10.004
– volume: 11
  start-page: 5752
  year: 2020
  ident: 3273_CR42
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19568-1
– volume: 383
  start-page: 1695
  year: 2020
  ident: 3273_CR51
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– volume: 5
  start-page: 1185
  year: 2020
  ident: 3273_CR11
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-00789-5
– volume: 30
  start-page: 1
  year: 2020
  ident: 3273_CR39
  publication-title: Rev. Med. Virol.
  doi: 10.1002/rmv.2141
– year: 2021
  ident: 3273_CR56
  publication-title: Emerg. Infect. Dis. J.
  doi: 10.3201/eid2704.210138
– volume: 40
  start-page: 37
  year: 2020
  ident: 3273_CR34
  publication-title: Inflamm. Regen.
  doi: 10.1186/s41232-020-00146-3
– year: 2021
  ident: 3273_CR38
  publication-title: Vaccines (Basel).
  doi: 10.3390/vaccines9010054
– volume: 144
  start-page: 3183
  year: 1990
  ident: 3273_CR26
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.144.8.3183
– volume: 27
  start-page: 505
  year: 2009
  ident: 3273_CR8
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.10.087
– volume: 8
  start-page: 1233
  year: 2020
  ident: 3273_CR37
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(20)30404-5
– volume: 383
  start-page: 1694
  year: 2020
  ident: 3273_CR49
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– year: 2021
  ident: 3273_CR43
  publication-title: BioRxiv.
  doi: 10.1101/2021.01.03.425141
– volume: 383
  start-page: 1695
  year: 2020
  ident: 3273_CR50
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2028468
– volume: 20
  start-page: 633
  year: 2020
  ident: 3273_CR13
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00410-0
– volume: 99
  start-page: 1239
  year: 2018
  ident: 3273_CR25
  publication-title: J. Gen. Virol.
  doi: 10.1099/jgv.0.001119
– volume: 74
  start-page: 1400
  year: 2013
  ident: 3273_CR19
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2013.05.017
– volume: 108
  start-page: 17
  year: 2020
  ident: 3273_CR31
  publication-title: J. Leukoc. Biol.
  doi: 10.1002/JLB.3COVR0520-272R
– year: 2020
  ident: 3273_CR35
  publication-title: JCI Insight.
  doi: 10.1172/jci.insight.140289
– volume: 8
  start-page: 687
  year: 2020
  ident: 3273_CR15
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(20)30193-4
– volume: 181
  start-page: 271
  year: 2020
  ident: 3273_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
SSID ssj0000529419
Score 2.4447732
Snippet Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination...
Abstract Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 23713
SubjectTerms 631/250/254
631/326/596/4130
ACE2
Angiotensin-converting enzyme 2
Angiotensin-Converting Enzyme 2 - metabolism
Antibodies
Antibodies, Neutralizing - immunology
Antibodies, Viral - immunology
Antibody-Dependent Enhancement
Cell Line
Cell lines
Clinical trials
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - metabolism
COVID-19 vaccines
Dengue fever
Humanities and Social Sciences
Humans
Infections
Interleukin 6
Interleukin-6 - metabolism
multidisciplinary
Myeloid Cells - immunology
Myeloid Cells - metabolism
Patients
SARS-CoV-2 - immunology
Science
Science (multidisciplinary)
Serine Endopeptidases - metabolism
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccine development
Vaccines
Vector-borne diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQpUpcEDuBgozEDazmxY4dH7tQtYjlQlFvlle1UpU8kbxDb_wN_h6_hJk4efSxXrjaE8uaxTMTj78h5EWprK9tCiyoJJhwnDMnMWu1zgbN61hFfOD87r08PhVvzuqza62-sCYswwNnxu1qfIrFo6qE4mDUwbpKpyhD42TSPCQ8fcHnXUumMqp3pcVCT69kSt7s9uCp8DVZhRVE4LNZueGJRsD-30WZvxZL_nRjOjqio9vk1hRB0r288zvkRmzvku3cU_LqHulB8HTZDVgFBGRdogcfPp0csoWmE4Zq_-3LV4rdH-jQUW9XfaTA3gvXhSs298QdaGzPUSHw5yEuMhdttUAb6MlbJukyg8XC2H1yevT648ExmzorMA8R2sCESGDnjbXSSyudU0k23kPkwJ3CmzQ4AQVkHkI5H5zykFRIX0VR2jJyCLA8f0C22q6NjwitUqhdSLrRyotYWg28rRGE3oGsolYFWcxcNn6CHcfuF5dmvP7mjcmSMSAZM0rGlAV5uf5mmUE3_kq9j8JbUyJg9jgAamQmNTL_UqOC7MyiN5MV9wZyPci-EGKxIM_X02B_eKli29itMg04DciKC_Iwa8p6JxxOR4jIFgVRGzq0sdXNmfbifMT4biSsK3lBXs3a9mNbf2bF4__BiifkZoVmgjU7eodsDZ9X8SlEXoN7NhrZd7-eKN0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1KQUbiBlazsWPHJwSFqkU8LhTtzfKzrYSSpckeeuvf4O_xS5jJq1oevSazkdcz4_nsGX9DyItcWV_aFFhQSTDhOGdO4q7VOhs0L2MR8YLzp8_y4Eh8WJbL8cCtHcsqpzWxX6hD4_GMfBdwNyBhpLt7vfrBsGsUZlfHFhrXyQ2kLsOSLrVU8xkLZrHEQo93ZXJe7bYQr_BOWYF1RBC5Wb4Rj3ra_n9hzb9LJv_Im_bhaP8OuT3iSPpmUPxdci3W98jNobPk-X3SgvrpqumwFgjEmkT3vnw7fMcWmo5Mqu2vi58Ue0DQrqHerttIYZJPXRPO2dQZt6OxPkGzwCNE_MhUulWDbKCHH5mkq4EyFp49IEf777_uHbCxvwLzgNM6JkQCb6-slV5a6ZxKsvIe8AN3CvNpsA4K2H8I5XxwysPWQvoiitzmkQPM8vwh2aqbOj4mtEihdCHpSisvYm41zG2JVPROBRu1yshimmXjR_Jx7IHx3fRJcF6ZQTMGNGN6zZg8Iy_n36wG6o0rpd-i8mZJpM3uHzRnx2b0QqPxXh-PqhCKQ4QI1hU6RRkqJ5PmIWVkZ1K9GX25NZeWl5Hn82vwQkyt2Do260EGQgfsjTPyaLCUeSQc1kjAZYuMqA0b2hjq5pv69KRn-q4kfFfyjLyarO1yWP-fiu2r_8UTcqtAB8CaHL1DtrqzdXwKyKpzz3r3-Q0aKCCC
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA/Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqIiQuiDehBRmJG1hkY8eOj7BQtYjHhaLeLD9pJZSsmuyhN_5G_x6_hBknWbRQkLgm48jyzHhmMjPfEPKsVNbXNgUWVBJMOM6Zkxi1WmeD5nWsIjY4f_goD4_Fu5P6ZIdUcy9MLtrPkJb5mp6rw172YGiwGazCAiAwuQzC9GsI3Y5SvZTLzX8VzFyJhZ76Y0reXLF0ywZlqP6r_Ms_yyR_y5VmE3Rwi9ycfEf6atztbbIT2zvk-jhN8uIu6YHldNUNWP8DZF2iy09fjt6whaYTemr_4_slxbkPdOiot-s-UjjYM9eFCzZPwx1obE9RFPC3IX5kLtdqgTbQo_dM0tUIEwvP7pHjg7efl4dsmqnAPPhmAxMigYY31kovrXROJdl4Dz4DdwpzaHD3CYg5hHI-OOUhnJC-iqK0ZeTgWnl-n-y2XRsfElqlULuQdKOVF7G0Gs62Rvh5p4KNWhVkMZ-y8RPgOM69-GZy4ps3ZuSMAc6YzBlTFuT5Zs1qhNv4J_VrZN6GEqGy84Pu_KuZRMdo7OXjUVVCcbAKwbpKpyhD42TSPKSC7M-sN5P-9gaiPIi7EFyxIE83r0HzMJ1i29itRxowFxAPF-TBKCmbnXC4F8EXWxREbcnQ1la337Rnpxndu5HwXckL8mKWtl_b-vtRPPo_8j1yo0KFwLocvU92h_N1fAze1eCeZHX6CR9JHjg
  priority: 102
  providerName: Springer Nature
Title The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production
URI https://link.springer.com/article/10.1038/s41598-021-03273-0
https://www.ncbi.nlm.nih.gov/pubmed/34887501
https://www.proquest.com/docview/2608262792
https://www.proquest.com/docview/2608538717
https://pubmed.ncbi.nlm.nih.gov/PMC8660863
https://doaj.org/article/914243e72473467dab29fe6d8b6f93df
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB6VVqBeKt6YlmiRkDiAqeNd73oPCKWhVRvRgoCg3Kx9mVaq7DRxJPLvmfUjKJBysrQeW6t5eGa8M98AvIqEMonKbWhFzkKmKQ0191mr0spKmrjY-Qbn8wt-OmajSTLZgm7cUcvA-cbUzs-TGs-u3_26WX5Ag3_ftIynh3N0Qr5RLPbFQeiOQ0zhd9AzCW-o522432B9x5L1Zds7s_nRXbhHUanRkfbXXFWN6L8pDP23mvKvI9XaU53ch702xCSDRicewJYrHsLdZujk8hHcoGaQaVn5MiEkK3My_Pzj7GPYl6QFWZ2_Jn44BKlKYtRi7ghy_0qXdhl2I3Mr4opLry_-36J_RVfTVSCtJWefQk6mDZYsrj2G8cnx9-Fp2A5eCA0GcFXIWI6fgVQpbrjiWoucp8ZgYEG18Adt-IFkmJgwoY3VwmDOwU3sWKQiRzH-MvQJbBdl4Z4BiXObaJvLVArDXKQkMjnxGPVaWOWkCKDf8TgzLSq5H45xndWn4zTNGhFlKKKsFlEWBfBm9cy0weT4L_WRF92K0uNp1wvl7GfWmmcmfcMfdSJmgqLrsErHMnfcpprnkto8gINO8FmnoxmmgpiceQTGAF6ubqN5-jMXVbhy0dCgT8GkOYCnjZ6sdtLpWQBiTYPWtrp-p7i6rCHAU47v5TSAt52u_dnW7ax4fusW9mE39kbg63TkAWxXs4V7gdFWpXtwR0xED3YGg9G3EV6Pji--fMXVIR_26j8YvdrIfgNEiyeF
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG8CBYwEJ4iajb12ckCIvrRLtwtCLeot9Su0EkqWbiq0N_4Gf4IfxS9hJo-tlkdvvSYTy_HMeD57XgDPI6XtQOcudCoXoTCch0bSqVUb7VI-8LGnBOe9iRweiHeHg8MV-NnlwlBYZbcn1hu1Ky3dka8j7kYkTOXu3ky_htQ1iryrXQuNRix2_fwbHtlmr0dbyN8Xcbyzvb85DNuuAqFFdFKFQuQo44nW0kotjVG5TKxFq8mNIi8Sar9A1C2Usc4oi4Ba2tiLSEeeI7iwHMe9AquC4y_1YHVje_Lh4-JWh_xmop-22TkRT9ZnaCEpiy2myCXECmG0ZAHrRgH_Qrd_B2n-4amtDeDOTbjRIlf2thG1W7Dii9twtellOb8DMxQ4Ni0rij5CsjJnm-8_jbbCfsra2q2zX99_MOo6waqSWX028wzZemJKNw-7XrwV88UxCSJdWtIgXbBYgbSOjcahZNOmSC0-uwsHl7L296BXlIV_ACzO3cC4PE1SZYWPdIprO6Di90Y57VMVQL9b5cy25c6p68aXrHa78yRrOJMhZ7KaM1kUwMvFN9Om2MeF1BvEvAUlFequH5Snn7NW77OUMgm5V7FQHG2S0yZOcy9dYmSecpcHsNaxPmt3j1l2LusBPFu8Rr0nZ44ufHnW0KCxwtN4APcbSVnMhOOujEiwH4BakqGlqS6_KU6O69riicRxJQ_gVSdt59P6_1I8vPgvnsK14f7eOBuPJruP4HpMykARQeka9KrTM_8YcV1lnrTKxODosvX3NzL9XUs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtQwGLZKEYgLYidQwEhwAmuS2LGTA0LQYdShpXCgaG6pt9BKKBmajNDceA1ehcfhSfj_LFMNS2-9Jo7l-N8--98IeRIqbRNdOOZUIZgwnDMj8dSqjXYZT3zsMcH53b7cORBvZ8lsg_wccmEwrHLQia2idpXFO_IR4G5AwljublT0YREfxpOX868MO0ihp3Vop9GxyK5ffoPjW_1iOgZaP43jyZuP2zus7zDALCCVhglRAL-nWksrtTRGFTK1FiwoNwo9SqAJBCBwoYx1RlkA19LGXoQ69ByAhuUw7wVyUfEkQhlTM7W630EPmoiyPk8n5OmoBluJ-WwxxjABamDhmi1sWwb8C-f-Ha75h8-2NYWTa-Rqj2Hpq47prpMNX94gl7qulsubpAbWo_OqwTgkGFYVdPv9p-mYRRntq7jWv77_oNh_gjYVtXpRewoEPjaVW7KhK29DfXmELInXlzjJEDZWwlhHp3tM0nlXrhae3SIH57Lzt8lmWZX-LqFx4RLjiizNlBU-1BnsbYJl8I1y2mcqINGwy7ntC59j_40veeuA52neUSYHyuQtZfIwIM9W38y7sh9njn6NxFuNxJLd7YPq5HPea4A8w5xC7lUsFAfr5LSJs8JLlxpZZNwVAdkaSJ_3eqTOT7k-II9Xr0EDoFtHl75adGPAbMG5PCB3Ok5ZrYSDfgZMGAVErfHQ2lLX35THR22V8VTCvJIH5PnAbafL-v9W3Dv7Lx6RyyC1-d50f_c-uRKjLGBoULZFNpuThX8AAK8xD1tJouTwvEX3N7SFYBs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+potential+of+COVID-19+patients%27+sera+to+cause+antibody-dependent+enhancement+of+infection+and+IL-6+production&rft.jtitle=Scientific+reports&rft.au=Shimizu%2C+Jun&rft.au=Sasaki%2C+Tadahiro&rft.au=Yamanaka%2C+Atsushi&rft.au=Ichihara%2C+Yoko&rft.date=2021-12-09&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft.spage=23713&rft_id=info:doi/10.1038%2Fs41598-021-03273-0&rft_id=info%3Apmid%2F34887501&rft.externalDocID=34887501
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon